1. Αποθετήριο Παραδοτέων Υποτρόφων Δράσεων ΕΣΠΑ Τριτοβάθμιας Εκπαίδευσης 2017-2023
2. Όλο το Αποθετήριο
3. Ερευνητικές ομάδες

Τύπος:	Αναρτημένη ανακοίνωση (poster)
Τίτλος:	New potential soluble guanylyl cyclase (sGC) activators: Design, synthesis and NMR-driven interaction studies with the Nostoc sp. HNOX domain
Συγγραφέας:	[EL] Ρουμάνα, Αγγελική[EN] Roumana, Aggeliki [EL] Αργυρίου, Αικατερίνη[EN] Argyriou, Aikaterini [EL] Μακρυνίτσα, Γαρυφαλλιά[EN] Makrynitsa, Garyfallia [EL] Χασάπη, Στυλιανή[EN] Chasapi, Styliani [EL] Ματσούκας, Μίνως-Τιμόθεος[EN] Matsoukas, Minos-Timotheos [EL] Τοπούζης, Σταύρος[EN] Topouzis, Stavros
Ημερομηνία:	15/08/2019
Περίληψη:	Soluble guanylyl cyclase (sGC) plays a crucial role in mediating the biological effects of nitric oxide (NO). It is a heterodimer consisting of one alpha (α1 or α2) and one beta (β1or β2) subunit, with a prosthetic heme group located in the β1 H-NOX regulatory domain. sGC catalyzes the conversion of guanosine triphosphate (GTP) to the second messenger cyclic guanosine monophosphate (cGMP), upon binding of nitric oxide (NO) to the heme group. A number of pathological states, in particular cardiovascular and pulmonary diseases have been at least partly attributed to impairment of the NO-sGC-cGMP pathway, due for example to low NO bioavailability and/or heme oxidation and subsequent sGC dysfunction. Besides NO donors, two functional classes of sGC agonists have been identified: the heme-dependent sGC stimulators such as the recently approved drug riociguat (BAY 63-2521) and the clinically evaluated vericiguat (BAY 1021189) as well as the heme-independent sGC activators, such as the amino dicarboxylic acid derivative cinagiguat (BAY 58-2667). Notably, the enzymatic activity of sGC by sGC activators is enhanced after oxidation or removal of the heme moiety due for example to oxidation of the heme iron and loss of the heme group from sGC, a change elicited by synthetic tricyclic oxadiazolone derivatives such as the closely related analogues ODQ and NS2028.
Γλώσσα:	Αγγλικά
Τόπος δημοσίευσης:	Mainz, Germany
Σελίδες:	1
DOI:	10.1186/s12967-019-1994-0.
ISSN:	1479-5876
Θεματική κατηγορία:	[EL] Φαρμακολογία και Φαρμακευτική[EN] Pharmacology and Pharmacy
Κάτοχος πνευματικών δικαιωμάτων:	© The Author(s) 2019.
Όροι και προϋποθέσεις δικαιωμάτων:	This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Διατίθεται ανοιχτά στην τοποθεσία:	https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-019-1994-0
Ηλεκτρονική διεύθυνση του τεκμηρίου στον εκδότη:	https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-019-1994-0
Ηλεκτρονική διεύθυνση περιοδικού:	https://translational-medicine.biomedcentral.com/
Τίτλος πηγής δημοσίευσης:	Journal of Translational Medicine
Τεύχος:	Supplement 2
Τόμος:	17
Σελίδες τεκμηρίου (στην πηγή):	31
Όνομα εκδήλωσης:	9th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Τοποθεσία εκδήλωσης:	Mainz, Germany
Ημ/νία έναρξης εκδήλωσης:	14/06/2019
Ημ/νία λήξης εκδήλωσης:	16/06/2019
Σημειώσεις:	Τhe research/project “Novel functional activators of the soluble Guanylate Cyclase (sGC)” ΕΔΒΜ-34, # 80436 is implemented through/has been co-financed by the Operational Program "Human Resources Development, Education and Lifelong Learning" and is co-financed by the European Union (European Social Fund) and Greek national funds
Εμφανίζεται στις συλλογές:	Ερευνητικές ομάδες